ACCUiN Next Generation Cancer Gene Analysis Panel
ACCUiN Next Generation Cancer Gene Analysis Panel
Product Number
CGA-48A (Index 1-24)
CGA-48B (Index 25-48)
CGA-48C (Index 49-72)
CGA-48D (Index 73-96)
Version
No. of Reactions
-
48 tests
<- List of Testing Kits
Principle
ACCUiN Next Generation Cancer Gene Analysis Panel is a qualitative test designed using multiplex polymerase chain reaction (Multiplex PCR) technology and next-generation sequencing (NGS) technology to detect specific gene mutations in the test samples. ACCUiN Next Generation Cancer Gene Analysis Panel is used to identify whether malignant solid tumor tissues contain single nucleotide variants (SNVs), multi-nucleotide variants (MNVs), insertions, deletions, or insertion/deletion (INDELs) mutations in the following genes: ALK (NM_004304), BRAF (NM_004333), EGFR (NM_005228), ERBB2 (NM_004448), ESR1 (NM_000125), GNAS (NM_000516), IDH1 (NM_005896), IDH2 (NM_002168), KIT (NM_000222), KRAS (NM_033360), MET (NM_001127500), NRAS (NM_002524), PDGFRA (NM_006206), PIK3CA (NM_006218), RET (NM_020975), and ROS1 (NM_002944).
ACCUiN Next Generation Cancer Gene Analysis Panel has undergone quality validation and functional verification to ensure performance stability and reproducibility. ACCUiN Next Generation Cancer Gene Analysis Panel accommodates at least 48 testing reactions.安奕次世代癌症基因序列分析套組通過品質確效與功能驗證,確保其性能穩定性和重現性。安奕次世代癌症基因序列分析套組可提供至少48個檢測反應。